Hypochlorous acid (HOCl), an oxidant produced by myeloperoxidase (MPO), induces protein and lipid oxidation, which is implicated in the pathogenesis of atherosclerosis. Individuals with mildly elevated bilirubin concentrations (i.e. Gilbert's syndrome; GS) are protected from atherosclerosis, cardiovascular disease (CVD) and related-mortality. We aimed to investigate Albumin-bound UCB efficiently and specifically (3.9-125 µM; P<0.05) scavenged taurine-, glycine-and N-α-acetyl-lysine-chloramines. These results were translated into Gunn rat and GS serum/plasma which showed significantly (P<0.01) reduced chloramine formation after MPO-induced oxidation. Protein carbonyl and MDA formation were also reduced after MPO oxidation in plasma supplemented with UCB (P<0.05; 25 µM and 50 µM, respectively).
Introduction
Unconjugated bilirubin (UCB), a potentially toxic by-product of haem catabolism, also possesses powerful antioxidant properties. Epidemiological studies report that individuals with elevated UCB are protected from the development of intimal hyperplasia, atherosclerosis and cardiovascular disease (CVD) [1] [2] [3] [4] [5] [6] [7] . Furthermore, higher UCB concentrations (in the absence of haemolytic or liver disease) are associated with reduced incidence of CVD-related mortality [8] [9] [10] [11] [12] . The mechanisms responsible for CVD protection are not clear, however may be related to the potent antioxidant properties of UCB, given the potential role of oxidation in the development and progression of atherosclerosis [13] .
Numerous in vitro reports demonstrate the radical scavenging activity of various bilirubin species, which protect proteins and lipids from oxidation. Current evidence indicates that UCB efficiently inhibits amino acid oxidation mediated by hydroxyl, hydroperoxyl and superoxide radicals generated by radiolysis [14] and irradiation [15] . Furthermore, UCB is a potent lipid chain-breaking antioxidant scavenging artificially generated peroxyl radicals (2,2'-Azobis(2-amidinopropane) dihydrochloride (AAPH) [16] and 2,2'-azobis(2,4-dimethylvaleronitrile) (AMVN) [17] and inhibits copper (Cu 2+ ) induced lipid oxidation [18] .
Whether, bilirubin and related compounds protect from oxidation mediated by biologically relevant myeloperoxidase (MPO) and hypochlorous acid (HOCl) [19] , remains underexplored. This is an important phenomenon to investigate, because MPO is strongly linked to the development of atherosclerosis [20] [21] [22] [23] . Evidence to support a role of MPO in the pathogenesis of atherosclerosis includes the deposition of MPO in atherosclerotic lesions [24, 25] , the extent of which is inversely related to plaque progression [26] . Myeloperoxidase generates HOCl, a potent oxidant, which reacts with most biological molecules and targets proteins for oxidation [27] . Reaction of HOCl with amine groups on proteins gives rise to . chloramines, which decompose to form protein carbonyls [28, 29] and can also induce the oxidation of low-density lipoprotein (LDL), which may be important in the development of atherosclerosis [30] .
Some controversy exists regarding the role of bilirubin and related compounds in scavenging MPO-derived oxidants. Bilirubin ditaurate (BRT; a synthetic water soluble form of UCB) and biliverdin (product of oxidised UCB) inhibit MPO-mediated chemiluminescence [31] but fail to protect guaiacol from MPO oxidation [19] . However, both compounds prevent human polymorphonuclear leukocyte α1-antiprotease inactivation and tissue proteolytic attack by reagent HOCl [19] . Interestingly, preliminary in vitro data indicate that albumin-bound UCB does not react readily with HOCl [31] . This result is surprising when considering that persons with Gilbert's syndrome (GS) [32] who possess mildly elevated UCB concentrations (> 17.1 µM), demonstrate reduced protein carbonyl concentrations [33] . Given that the decomposition of intermediate chloramines is a pathway responsible for the formation of protein carbonyls, these observations support a potential role for UCB in the inhibition of MPO activity, and / or the scavenging of HOCl, or chloramines.
Whether higher, physiologically relevant, UCB concentrations scavenge HOCl or prevent protein oxidation (e.g. chloramine/protein carbonyl formation) in plasma samples remains unpublished.
Therefore, the aim of this study was to investigate whether serum/plasma samples with exogenous UCB supplementation or endogenously elevated UCB in serum/plasma from unique models of benign hyperbilirubinemia (Gunn rat and human GS) protect from protein and lipid oxidation induced by reagent and enzymatically-generated HOCl. We hypothesised that bilirubin would protect from protein oxidation, by quenching HOCl-induced chloramine .
formation. These data may help to rationalise the association between bilirubin and protection from CVD.
Methods

Human subjects
Forty-two subjects (21 GS; 21 controls) were recruited and matched for gender, age, and body mass index (BMI). Equal numbers of female and male subjects existed in each group (11:11) . A female control subject with normal UCB concentrations (10.3 µM) was used as a quality control for in vitro experimentation (ie. exogenous UCB supplementation for HOCl and MPO oxidation). Fasting human blood was collected in serum and ethylenediaminetetraacetic acid (EDTA) vacutainers. The recruitment of human subjects received ethical approval (MSC/02/10/HREC) from the Griffith University Human Research
Ethics Committee prior to experimentation commencing.
Animals
Breeding pairs of heterozygote (genotyped) Gunn rats were imported from the Rat Research and Resource Center (Columbia, MO, USA) and kept within an animal housing facility at
Griffith University (12-h light:dark cycle, constant temperature (22 °C) and humidity (60%)).
Rats had continuous access to standard laboratory food pellets (Speciality Feeds, Glen Forrest, Australia) and fresh water. Female homozygous Gunn rat offspring were assumed to possess jaundice at birth, were ear-tagged, and housed together with female littermate (non-jaundiced) controls after weaning. Gunn rats (n=9) and littermate controls (n=5) at 12 months of age were anesthetized using intraperitoneal injection of pentobarbital sodium (concentration 60 mg/mL; 100 µL/100 g). A midline laparotomy was performed, and approximately 5 mL of whole blood was collected from the thoracic cavity using a syringe and was transferred into . serum vacutainers and prepared for analysis (see section 2.3). All procedures were approved by the Griffith University Animal Ethics Research Committee prior to experimentation commencing (MSC/06/12).
Sample preparation
Whole blood was centrifuged (Thermo Scientific 5810R, Australia) at 2500 x g for 10 min (4 °C). Serum/plasma aliquots were prepared immediately and stored at −80 °C until analysis.
Human serum samples were used for biochemistry, antioxidant activities and HOCl oxidation, whereas EDTA plasma samples were used for MPO oxidation, measurement of chloramine, protein carbonyl and malondialdehyde (MDA) concentrations. Serum samples obtained from animals were used to perform all analyses. All reagents used were of analytical reagent grade or better and obtained from Sigma-Aldrich (Australia) unless otherwise indicated.
Serum biochemistry
Serum samples from animals were diluted 1:1 with distilled water and analysed for the activity of liver enzymes (alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase), glucose, uric acid and lipid parameters including total cholesterol, triglycerides and high-density lipoprotein using commercially available kits on a COBAS Integra 400 blood chemistry analyser (Roche Diagnostics, Australia). Cholesterol analyses were conducted using appropriate lipid standards (Calibrator for Automated Systems Lipids) and quality controls (Precinorm Control Clin Chem Multi 1 and 2; Roche Diagnostics, Australia). Total non-thiol antioxidant capacity including ferric reducing ability of plasma (FRAP) [34] was also assessed on an open channel of the COBAS Integra analyser. All analyses were conducted in duplicate. 
Determination of bilirubin concentrations
Serum UCB concentrations were quantified using high-performance liquid chromatography (HPLC) and a photodiode array detector (Waters, Australia) as previously described [35] . A slight variation to this method included the use of C18 reserve-phase HPLC guard and analytical column (4.6 mm x 150 mm, 3 µm; Phenomenex, Australia) that was perfused at 1 ml/min. Extracted samples were injected (100 µL) with a run time 15 min in duplicate.
Unconjugated bilirubin (Frontier Scientific, USA; 0-100 µM) served as an external standard and was detected at 450 nm.
Induction of hypochlorous acid (HOCl) oxidation
Human quality control samples (serum) were thawed to room temperature and centrifuged at 2500 x g for 5 min and diluted (1:10 for reagent HOCl oxidation) with deionised water.
Sodium phosphate buffer (0.1 M, pH 7.4) was prepared and treated with chelex resin prior to use, to minimise contamination with transition metal ions [36] . Buffer was stored at room temperature and used as a control in oxidation assays. Unconjugated bilirubin stock solutions were prepared fresh in 0.05 M sodium hydroxide (NaOH). Bilirubin solutions were protected from light using foil covered containers and used immediately. A final UCB concentration (1.56-25 µM; 5 µL) or NaOH as control (0.05 M; 5 µL) were added to diluted serum samples in new reaction tubes. Hydrochloric acid (HCl; 0.05 M; 5 µL; Ajax Finechem, Australia) was then added to the serum mixture to neutralise NaOH. Hypochlorous acid stock (1 mM) was prepared fresh in sodium phosphate buffer and 20 µL was added to the serum mixture (final HOCl concentration of 100 µM) and incubated in the dark at room temperature for 5 min.
The serum mixture was transferred to 96-well plate which was then analysed for chloramine formation (see section 2.11).
.
Reaction of unconjugated bilirubin with biologically relevant chloramine species
For in vitro experiments, which aimed to determine whether exogenous UCB could directly quench physiologically-relevant chloramines, UCB was associated with bovine serum albumin (BSA) to facilitate its aqueous solubility and to ensure that bilirubin was present in a biologically relevant form. Taurine-glycine-and N-α-acetyl-lysine chloramines (250 µM)
were formed by the addition of HOCl to each amine in a 1:9 HOCl:amino acid molar ratio for 5 mins prior to the addition of BSA (250 µM) in the presence and absence of varying amounts of UCB (0 -125 µM). UCB was added to BSA as a concentrated stock solution (10 mM) prepared in NaOH (0.05 M). Samples were incubated at 21 °C for 5 min prior to chloramine quantification (described below).
Induction of myeloperoxidase/hydrogen peroxide (MPO/H 2 O 2 ) oxidation
Protein oxidation induced by MPO (PLANTA Natural Products, Austria) was conducted according to the method of Summers et al. [37] . 
Measurement of protein concentrations
Human and animal serum protein concentrations were determined according to the bicinchoninic acid protein assay kit (Thermo Scientific, Australia). The samples were read at 540 nm using a 96-well plate reader (Thermo Scientific, Multiskan FC, Australia). The assay was performed in triplicate and results expressed in mg/mL of protein. The co-efficient of variation for this method was 3.4%.
Measurement of reduced thiol concentrations
Reduced thiol concentrations were quantified with 5,5-dithiobis(2-nitrobenzoic acid) (DTNB) reagent. Reduced thiols react with DTNB to generate 5-thio-2-nitrobenzoic acid (TNB), which was quantified in triplicate at 415 nm using a 96-well plate reader (Multiskan FC, Thermo Scientific, Australia) according to the method of Hawkins et al. [36] . Reduced glutathione (0-0.5 mM) served as an external standard. Thiol concentrations were expressed initially in µM and then converted to nmol/mg of protein. The co-efficient of variation for this method was 2.6%.
Measurement of chloramine concentrations
Chloramine is a stable product of protein oxidation and was quantified according to previously published protocols [38] . 
Measurement of protein carbonyl concentrations
Detection of protein carbonyl with 2,4-dinitrophenylhydrazine was performed using enzymelinked immunosorbent assay (ELISA; Sapphire Biosciences, Australia) with the abovementioned 96-well plate reader. Each sample was assayed in triplicate, with experiments repeated five times and results expressed in nmols/mg of protein. The co-efficient of variation for this assay was 6.8%.
Measurement of plasma malondialdehyde concentrations
Malondialdehyde in human EDTA plasma was quantified in triplicate using HPLC via a modified method of Londero et al. [39] , performed with a Hitachi Model F-1050 fluorescence spectrophotometer detector set at 532 nm excitation and 563 nm emission and a HPLC column (125 mm x 4mm, 5 µm; Merck, Austria). The extracted sample was injected (20 µL) with a retention time of 4 min with a flow rate of 1.3 mL/min. 1,1,3,3-Tetraethoxypropane (Sigma-Aldrich, Austria) ranging from 0-8.12 µM served as an external standard and the co-efficient of variation for this method was 8.8%.
Statistical analysis
SigmaPlot software (version 11.0) was used to analyse all data. Two-tailed, unpaired t tests (Student's t test or Mann-Whitney rank sum test) tested for significant differences in variables between GS individuals or Gunn rats and controls. One way analysis of variance (ANOVA) followed by Dunn's post-hoc analysis tested the dose effect of UCB on oxidized product formation. Group data are presented as a mean±standard deviation. Pearson
. correlation tested the relationship between UCB and oxidation products. The level of significance was set at P<0.05.
Results
Inhibition of chloramine formation by HOCl and MPO mediated oxidation
Hypochlorous acid reacts with amine groups on proteins to produce chloramines [28] .
When HOCl was added to plasma, exogenous UCB inhibited chloramine formation in a dose- To confirm whether endogenously elevated UCB would therefore protect from chloramine formation, serum/plasma samples from Gunn rats and humans with GS were also Figure 3A ). Gunn rats have significantly improved antioxidant status (Ferric reducing ability of plasma, FRAP; P<0.01; Figure 4A ) which was strongly and positively correlated with UCB concentrations (r=0.950; P<0.01; Figure S2A ). Chloramine formation was inhibited by ~40% in hyperbilirubinemic Gunn rat serum, compared to control samples (0.20±0.02 vs.
0.34±0.07 nmols/mg protein; P<0.01; Figure 5A ) when exposed to MPO/HOCl oxidation and was negatively correlated with UCB concentration (r=-0.840, P<0.001; Figure S3A ). A subset of plasma samples from GS subjects with mildly elevated endogenous UCB concentrations were obtained from a previous study [33] . Similarly, UCB concentrations were significantly elevated in GS compared to controls (34.8±18.5 vs. 10.5±2.87 µM; P<0.01; Figure 3B ), who tended to experience elevated FRAP concentrations (P=0.095; Figure 4C ).
Serum UCB concentration was significantly correlated with FRAP concentrations in the human cohort (r=0.521; P<0.01; Figure S2C ). Reduced thiol concentrations were also significantly elevated in GS (P=0.002; Figure 4D ) and were also positively correlated to UCB concentrations (r=0.403; P<0.01; ( Figure S2D ). Gilbert's syndrome plasma was also protected from MPO-mediated chloramine formation compared to controls (0.09±0.06 vs.
0.14±0.07 nmols/mg protein; P<0.01; Figure 5B ) with chloramine formation being negatively correlated with UCB concentrations (r=-0.486, P<0.01; Figure S3B ). 
Inhibition of protein carbonyl formation by MPO mediated oxidation
Chloramines decompose to yield protein carbonyls, a stable biomarker of protein oxidation and CVD risk [28, [40] [41] [42] . Formation of protein carbonyl was inhibited in a concentration dependent manner with ≥25 µM UCB significantly inhibiting protein oxidation (P<0.05; Figure 6A ).
Inhibition of malondialdehyde formation by MPO mediated oxidation
Oxidative damage to lipids, particularly LDL, is associated with the severity, and potentially development of CVD [43, 44] . 
Discussion
The present study demonstrates that UCB protects proteins and lipids from MPO induced oxidation, which represents an important biological source of oxidants implicated in disease pathogenesis [45] [46] [47] . Plasma supplemented with UCB reduced HOCl and MPOinduced chloramine formation. Importantly, albumin-bound UCB directly quenched taurine-, glycine-and N-α-acetyl-lysine-chloramines at low micromolar concentrations. Chloramine formation, induced by MPO, was also significantly inhibited by UCB in two physiologically relevant models of benign hyperbilirubinemia; in serum/plasma from humans with GS and Gunn rats. Unconjugated bilirubin further inhibited the formation of chloramine decomposition products including protein carbonyl and malondialdehyde, which was likely mediated by direct quenching of chloramine by UCB. Therefore, these data provide a biologically relevant mechanism to explain protection from protein and lipid oxidation and a hypothetical mechanism that may contribute to protection from atherosclerosis observed in individuals with mildly elevated UCB concentrations.
Individuals with benign hyperbilirubinemia often possess impaired uridine diphosphate-glucuronosyl transferase (UGT1A1) activity [48, 49] , underpinned by an increased TA repeat polymorphism in the UGT1A1 gene promoter, which contributes to elevated UCB levels observed in GS. Epidemiological reports indicate that hyperbilirubinemic individuals are protected from atherosclerosis and CVD [1] [2] [3] [4] 6, 12] .
Bilirubin is an endogenous antioxidant, which efficiently scavenges various oxidant species in vitro [14] [15] [16] 18, 50, 51] . For example, one molecule of albumin-bound bilirubin efficiently inhibits the oxidation of albumin-bound fatty acids by scavenging two peroxyl radicals [16] .
Unconjugated bilirubin protects against oxidative modification of BSA, lysozyme and melittin from radicals induced by irradiation of oxygen [15] . In a similar study, bilirubin also . efficiently inhibited protein carbonyl formation mediated by radiolysis [14] . Nevertheless, testing whether UCB resists protein and lipid oxidation generated from biologically relevant systems, such as MPO-generated HOCl, in physiologically relevant models of hyperbilirubinemia is sparse and of great importance, if we are to understand the potential physiological importance of UCB in protecting from disease.
Reagent HOCl oxidation
Blood plasma is rich in proteins and amino acids including lysine, tyrosine and methionine, which are particularly susceptible to oxidative modification by HOCl [37, 52] .
Treatment of proteins with HOCl induces protein carbonyl formation via the hydrolysis of chloramines, which are considered biomarkers of protein oxidation [53, 54] . Chloramines also decompose via pathways leading to protein side-chain modification, fragmentation and crosslinking [53] . However, the mechanisms by which UCB, at physiological concentrations, might inhibit the formation of these oxidized products in plasma are poorly described. In the present study, exogenous UCB (15.6-250 µM; after correcting for serum dilution) efficiently inhibited reagent HOCl (100 µM) induced chloramine formation (measured at 5 min) in a concentration dependent manner, with 15.6 µM representing the lowest effective concentration. To determine whether bilirubin could directly quench chloramines we preformed chloramine on taurine, glycine and N-α-acetyl lysine. These biologically relevant chloramines react readily with protein thiols [37] and we show that albumin-bound UCB quenched chloramine formation at low micromolar concentrations (ie. 3.9-7.8 µM). These observations indicate that bilirubin co-operates with albumin to neutralise HOCl-mediated chloramine, which could otherwise decompose and further oxidize proteins and lipids. These data suggest that normal physiological UCB concentrations (5-10 µM) could contribute to quenching chloramine, and at bilirubin concentrations in GS (≥17.1 µM) may strongly inhibit . chloramine formation. We show that 15.6 µM albumin-bound UCB quenched ~47, ~23, ~35 µM taurine, glycine and lysine chloramine species, suggesting that bilirubin quenches a ~1.5-3 molar excess of chloramine, when associated with albumin.
These observations are in general agreement with previous publications showing that BRT (≥25 µM), a synthetic water soluble bilirubin analogue, rapidly and efficiently scavenged HOCl (100 µM) in a concentration-dependent manner [19] . The authors concluded that higher concentrations of bilirubin (conjugated or unconjugated) within pathological conditions (eg. liver failure, GS, Dubin-Johnson, Rotor, Crigler-Najjar syndromes or conjugated bilirubin in bile) [55, 56] may scavenge HOCl in vivo, however, did not test this specifically [31] . Interestingly, albumin-bound UCB (~15 µM) did not react efficiently with reagent HOCl (50 µM) in vitro [31] . These observations may also have been affected by the low concentration of bilirubin and HOCl tested in this in vitro system, the matrix within which it was tested (a BSA solution), which did not reflect the composition of human plasma or potentially that oxidation products of bilirubin contribute further to neutralising HOCl [19] .
Despite these limitations, these data indicated that unconjugated bilirubin was unlikely to react sufficiently with HOCl to mediate protection from protein oxidation. 
MPO-generated HOCl oxidation
Stocker et al. showed that BRT (10 µM) did not inhibit the MPO-H 2 O 2 mediated oxidation of guaiacol; however, showed that the tetraguaiacol product formed from guaiacol oxidised BRT [19] . The failure of BRT to inhibit guaiacol oxidation might be influenced by the relatively short oxidation period (ie. 5 min) used during testing. Plasma treated with MPO induces chloramine formation gradually after 30 mins of incubation [37] . In the present study however, the reaction of plasma with MPO for 30 mins resulted in chloramine formation, which was dose-dependently inhibited by exogenous UCB (12.5-100 µM). More importantly,
Gunn rat serum and GS plasma were less susceptible to MPO-induced chloramine formation and suggested a dose response effect of UCB. Gunn rats possessed a greater antioxidant status (FRAP) versus controls, reflecting the contribution of bilirubin to antioxidant status in this assay. Strong, significant correlations between reduced thiols, glutathione and UCB concentrations were reported in humans within our previous study [33] and are in agreement with elevated circulating sulfhydryl groups reported in another GS cohort [57] . These data suggested dose-dependent protection from HOCl oxidation associated with UCB may also be influenced by improved antioxidant capacity (ie. reduced thiols), which may reduce chloramine formation by providing a kinetically more favourable target for reaction in vivo [27] . However, we have demonstrated that albumin-bound UCB efficiently reacts with preformed chloramine species, providing a novel mechanism to explain how UCB protects from MPO induced oxidation. Investigation of the rate constant for chloramine decomposition in the presence of bilirubin would provide important information as to whether bilirubin represents a kinetically favourable target for oxidation. However, methodological limitations including the need to associate bilirubin with BSA (which contains sulfhydryl groups that compete for oxidation) and/or sufficiently sensitive, specific
. and rapid quantitation of bilirubin currently preclude the accurate quantification of such a rate constant.
Plasma-derived chloramines decompose relatively slowly (over 4 hr) resulting in the formation of protein carbonyls [29, 58] . Myeloperoxidase has previously been implicated as a source of protein carbonyls in vivo [59] and reduced protein carbonyl concentrations are associated with a decreased risk of CVD events [41, 60, 61] . Individuals with a greater UCB concentrations (≥ 40 µM), have reduced circulating protein carbonyls, which are negatively correlated with the UCB concentration in vivo [33] . Our present data shows that exogenous UCB supplementation (25-100 µM) effectively inhibited secondary protein carbonyl formation mediated by MPO-generated HOCl. Cumulatively, these data provide a mechanistic link to explain how endogenously elevated UCB inhibits protein carbonyl formation, via the direct quenching of intermediate chloramine formation.
Previous studies have reported that exposure of LDL to reagent HOCl or MPO-generated
HOCl induces the modification of amino acid residues of apolipoprotein B-100 (apo B) associated with LDL, followed by lipid peroxidation [30, 43, [62] [63] [64] . Chloramines give rise to nitrogen centred radicals, in turn leading to the generation of secondary radicals [29, 53] .
These radicals derived from chloramine on apo B could initiate lipid peroxidation in LDL [30] . However, no data exists to link UCB and inhibition of lipid oxidation mediated by MPO-generated HOCl. We show that addition of exogenous UCB (≥50 µM) to plasma significantly inhibits MPO-generated MDA formation, a biomarker of lipid oxidation.
Together these data suggest an important role of UCB in protecting protein and lipid oxidation by directly scavenging intermediate chloramines [30, 65] , which could potentially contribute to CVD protection ( Figure 7 ). It should be noted however, such a statement is . speculative and that animal models of CVD development (ie. ApoE -/-mice), with endogenously elevated and decreased bilirubin would need to be developed to provide a conclusive evidence for a role of bilirubin in atheroprotection.
Conclusion
This translational report shows that UCB, at physiologically relevant concentrations, protects from protein and lipid induced MPO-generated HOCl oxidation and suggests that this inhibition is accompanied by direct scavenging of chloramine by albumin-bound UCB.
Inhibition of protein oxidation is reported upon exogenous UCB addition to human plasma, and within two independent models (rats and humans) of hyperbilirubinemia. These data provide a biologically relevant mechanism which could potentially contribute to reducing the incidence of CVD in GS. If this hypothesis is confirmed, strategies aimed at modifying haem catabolism and bilirubin metabolism, leading to mildly elevated circulating bilirubin, may provide a new target for therapy in humans at risk of atherosclerosis [66] . 
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